TITLE

Sustained reduction in bronchial hyperresponsiveness with inhaled fluticasone propionate within three days in mild asthma: time course after onset and cessation of treatment

AUTHOR(S)
Sovij''rvi A R A; Haahtela T; Ekroos H J; Lindqvist A; Saarinen A; Poussa T; Laitinen L A
PUB. DATE
June 2003
SOURCE
Thorax;Jun2003, Vol. 58 Issue 6, p500
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
BACKGROUND: Bronchial hyperresponsiveness (BHR) is characteristic of asthmatic airways, is induced by airway inflammation, and is reduced by inhaled corticosteroids (ICS). The time course for the onset and cessation of the effect of ICS on BHR is unclear. The effect of inhaled fluticasone propionate (FP) on BHR in patients with mild persistent asthma was assessed using time intervals of hours, days and weeks. METHODS: Twenty six asthmatic patients aged 21-59 years were selected for this randomised, double blind, parallel group study. The effect of 250 micro g inhaled FP (MDI) administered twice daily was compared with that of placebo on BHR assessed using a dosimetric histamine challenge method. The dose of histamine inducing a decrease in forced expiratory volume in 1 second (FEV(1)) by 15% (PD(15)FEV(1)) was measured before and 6, 12, 24 and 72 hours, and 2, 4 and 6 weeks after starting treatment, and 48 hours, 1 week and 2 weeks after cessation of treatment. Doubling doses of changes in PD(15)FEV(1) were calculated and area under the curve (AUC) statistics were used to summarise the information from individual response curves. RESULTS: The increase in PD(15)FEV(1) from baseline was greater in the FP group than in the placebo group; the difference achieved significance within 72 hours and remained significant until the end of treatment. In the FP group PD(15)FEV(1) was 1.85-2.07 doubling doses above baseline between 72 hours and 6 weeks after starting treatment. BHR increased significantly within 2 weeks after cessation of FP treatment. CONCLUSIONS: A sustained reduction in BHR to histamine in patients with mild asthma was achieved within 3 days of starting treatment with FP at a daily dose of 500 micro g. The effect tapered within 2 weeks of cessation of treatment.
ACCESSION #
10631584

 

Related Articles

  • Inhaled corticosteroids modulate the (+)insert smooth muscle myosin heavy chain in the equine asthmatic airways. Boivin, Roxane; Vargas, Amandine; Lefebvre-Lavoie, Josiane; Lauzon, Anne-Marie; Lavoie, Jean-Pierre // Thorax;Dec2014, Vol. 69 Issue 12, p1113 

    Rationale Overexpression of the (+)insert smooth muscle myosin heavy chain (SMMHC) isoform could contribute to airway bronchospasm by increasing the velocity of contraction. Whether the (+)insert isoform is present in the small airways and its expression is reversible in asthma are unknown....

  • Perception of airway narrowing during reduction of inhaled corticosteroids and asthma exacerbation.  // Thorax;Dec2003, Vol. 58 Issue 12, p1042 

    Background: The perception of airway narrowing is reduced in subjects with severe asthma and may be related to the severity of airway inflammation. A study was undertaken to determine if the perception of airway narrowing changes during the reduction of inhaled corticosteroid (ICS) dose or...

  • Airway Hyperresponsiveness.  // Encyclopedic Reference of Molecular Pharmacology;2004, p17 

    A definition of the term "airway hyperresponsiveness" is presented. It refers to an exaggerated propensity for airways to narrow easily in response to a variety of stimuli. stimuli. It leads to clinical symptoms of dyspnea and wheezing after exposure to allergens, viral infections, environmental...

  • Diagnosis and treatment of refractory asthma. URSO, D. L.; VINCENZO, D.; PIGNATARO, F.; ACRI, P.; CUCINOTTA, G. // European Review for Medical & Pharmacological Sciences;Sep/Oct2008, Vol. 12 Issue 5, p315 

    Asthma is an inflammatory disorder of the airway associated with airflow obstruction and bronchial hyperresponsiveness that varies in severity across the spectrum of the disease. Asthma affects 5-7% of the population of North America and Europe, and the prevalence is increasing. Most patients...

  • Feasibility and acceptability of using bronchial hyperresponsiveness to manage asthma in primary care: a pilot study. Turton, James A.; Glasgow, Nicholas J.; Brannan, John D. // Primary Care Respiratory Journal;Mar2012, Vol. 21 Issue 1, p28 

    Aims: To determine if indirect testing for bronchial hyperresponsiveness (BHR) to monitor inhaled corticosteroid (ICS) treatment in asthma is feasible and acceptable in primary care. Methods: Fourteen adult patients with asthma aged 22-70 years (4M:10F, forced expiratory volume in 1 s >70%...

  • Pharmacological Factors that Influence the Choice of Inhaled Corticosteroids. Edsbacker, S. // Drugs;Dec1999 Supplement 4, Vol. 58 Issue 6, p7 

    Local therapeutic effect relative to the risk of adverse effects of inhaled drugs, i.e. airway selectivity, is determined by the efficiency of the delivery system and the physicochemical and pharmacokinetic properties of the drug molecule. For the inhaled corticosteroid formulations, many of the...

  • Exercise-induced bronchoconstriction and non-specific airway hyperreactivity in patients suffering from bronchial asthma. Novković, Dobrivoje; Škuletić, Vesna; Vulin, Aleksandra; Cvetković, Gordana // Vojnosanitetski Pregled: Military Medical & Pharmaceutical Journ;Feb2014, Vol. 71 Issue 2, p191 

    Background/Aim. Physical activity is a common stimulus of asthmatic symptoms manifestation. Airway hyperreactivity is a predisposing cause of exercise induced bronchial obstruction, diagnosed by histamine inhalation. The aim of this study was to determine the relation between the amounts of...

  • Potential of Immunoglobulin A to Prevent Allergic Asthma. Gloudemans, Anouk K.; Lambrecht, Bart N.; Smits, Hermelijn H. // Clinical & Developmental Immunology;2013, p1 

    Allergic asthma is characterized by bronchial hyperresponsiveness, a defective barrier function, and eosinophilic lower airway inflammation in response to allergens. The inflammation is dominated by Th2 cells and IgE molecules and supplemented with Th17 cells in severe asthma. In contrast, in...

  • INVESTIGAREA REACTIVITÄ‚Å¢II BRONÅžICE. CHESTIONARUL ECRHS II VERSUS TESTUL PD20 VEMS HISTAMINÄ‚. SOCACIU, ANDREEA-IULIA; RÂJNOVEANU, ARMÂND GABRIEL; COCÂRLĂ, ARISTOTEL; BOLBOACĂ, SORANA DANIELA // Acta Medica Transilvanica;mar2013, Vol. 18 Issue 1, p73 

    Bronchial hyperreactivity (BHR), common in asthma occurs in other diseases such as chronic airway obstruction. Our aim is the validation of the ECRHS II questionnaire (The European Community Respiratory Survey II) in detecting BHR. Methodology: ECRHS II questionnaire was applied on a group of...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics